Retrospective cohort study on the safety and efficacy of docetaxel in Japanese non ‐small cell lung cancer patients with nondialysis chronic kidney disease stage 3b or higher

ConclusionDocetaxel is a reasonable option for NSCLC patients with nondialysis CKD stage 3b or higher. Dose reduction of docetaxel is also a possibility for NSCLC patients with CKD stage 3b or higher.

Source: Thoracic Cancer - October 20, 2019 Category: Cancer & Oncology Authors: Satoshi Anai, Ritsu Ibusuki, Tomoaki Takao, Yuko Sakurai, Junko Hisasue, Yoichi Takaki, Naohiko Hara Tags: ORIGINAL ARTICLE Source Type: research